[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614194":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":15,"locations":21,"responsibleParty":36,"collaborators":40,"id":44,"slug":7,"hasResults":45,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":7,"eligibilityCriteria":49,"healthyVolunteers":45,"sex":50,"minAge":51,"maxAge":7,"enrollmentInfo":52,"targetDuration":55,"studyType":56,"phases":7,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},{"fullName":5,"class":6},"UMC Utrecht","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":13},"DRUG","Dupilumab","In the Netherlands, the standard care for patients with moderate-to-severe prurigo nodularis who have failed or are contraindicated to conventional systemic immunosuppressive treatments consists of 300 mg of dupilumab administered subcutaneously every two weeks, following a loading dose of 600 mg administered subcutaneously.",[14],"Dupixent",[16],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},"Marjolein de Bruin-Weller, Professor","CONTACT","000","m.s.debruin-weller@umcutrecht.nl",[22],{"facility":23,"status":24,"city":25,"state":25,"zip":7,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":34},"University Medical Center Utrecht","RECRUITING","Utrecht","Netherlands","NL",{"type":29,"coordinates":30},"Point",[31,32],5.12222,52.09083,{"lat":32,"lon":31},[35],{"name":17,"role":18,"phone":19,"phoneExt":7,"email":20},{"type":37,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","Dr M.S. de Bruin-Weller","Professor",[41],{"name":42,"class":43},"Sanofi","INDUSTRY","100614194",false,"NCT07276425","Early and Long-Term Efficacy and Immune Changes With Dupilumab in Prurigo Nodularis","Early and Long-term Clinical Efficacy and Local Tissue and Peripheral Immune Changes Following Dupilumab Treatment in Prurigo Nodularis Patients","Inclusion Criteria:\n\n* Adult patients with moderate-to-severe prurigo nodularis starting dupilumab treatment\n\nExclusion Criteria:\n\n* Unwilling to participate in the BioDay registry\n* (For translational endpoints only) Unwilling to participate in UMC Utrecht Biobank","ALL","18 Years",{"count":53,"type":54},40,"ESTIMATED","52 Weeks","OBSERVATIONAL","With the arrival of dupilumab as the first available targeted therapy for PN, there is an unmet need for real-world data and translational research on the working mechanism of dupilumab on PN, to optimize individualized targeted treatment.",[59],"Prurigo Nodularis (PN)",[61,62],"prurigo nodularis","dupilumab","2025-12-11",{"date":65,"type":66},"2025-12-18","ACTUAL",{"date":68,"type":66},"2025-06-01",{"date":70,"type":54},"2028-06-01",{"name":5,"class":6},1]